Scholarlink

Purpose of Review <p><i>Acinetobacter baumannii</i> is a major cause of healthcare-associated infections and is classified by the World Health Organization as a critical priority pathogen due to its rapidly increasing antibiotic resistance. Although numerous studies have reported its prevalence and treatment strategies, a comprehensive review till date is lacking. This review aims to analyze the global prevalence, antimicrobial resistance (AMR) patterns, associated infections, and resistance genes of <i>A. baumannii</i> reported between 2015 and 2026.</p> Recent Findings <p>A global rise in multidrug-resistant and carbapenem-resistant <i>A. baumannii</i> has been observed, particularly in Asia, the Middle East, and Africa. Extensively drug-resistant and pandrug-resistant strains are increasingly reported in China, Iran, Greece, and Eastern Europe, with resistance rates exceeding 90% in some regions.</p> Summary <p> These findings highlight a critical global urge in drug-resistant <i>A. baumannii</i>, severely limiting treatment options and emphasizing the urgent need for novel and alternative therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence of Drug-Resistant Acinetobacter baumannii Infections and their Threats in Public Health on Global Scale

  • 期刊论文

  • 发表日期：

    2026年5月21日

查看全文
  • Lekha Sree Venkatesan,
  • Saheb Ali,
  • Palanivel Sathishkumar

摘要

Purpose of Review

Acinetobacter baumannii is a major cause of healthcare-associated infections and is classified by the World Health Organization as a critical priority pathogen due to its rapidly increasing antibiotic resistance. Although numerous studies have reported its prevalence and treatment strategies, a comprehensive review till date is lacking. This review aims to analyze the global prevalence, antimicrobial resistance (AMR) patterns, associated infections, and resistance genes of A. baumannii reported between 2015 and 2026.

Recent Findings

A global rise in multidrug-resistant and carbapenem-resistant A. baumannii has been observed, particularly in Asia, the Middle East, and Africa. Extensively drug-resistant and pandrug-resistant strains are increasingly reported in China, Iran, Greece, and Eastern Europe, with resistance rates exceeding 90% in some regions.

Summary

These findings highlight a critical global urge in drug-resistant A. baumannii, severely limiting treatment options and emphasizing the urgent need for novel and alternative therapeutic strategies.